Your browser doesn't support javascript.
loading
Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann, Hendrik; Lallous, Nada; Ozistanbullu, Deniz; Beraldi, Eliana; Paul, Naman; Dalal, Kush; Fazli, Ladan; Haferkamp, Axel; Lejeune, Pascale; Cherkasov, Artem; Gleave, Martin E.
Afiliação
  • Borgmann H; Department of Urologic Sciences, The Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada; Department of Urology, University Medicine Johannes Gutenberg-University Mainz, Mainz, Germany.
  • Lallous N; Department of Urologic Sciences, The Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada.
  • Ozistanbullu D; Department of Urologic Sciences, The Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada; Department of Urology, University Hospital Frankfurt, Frankfurt, Germany.
  • Beraldi E; Department of Urologic Sciences, The Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada.
  • Paul N; Department of Urologic Sciences, The Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada.
  • Dalal K; Department of Urologic Sciences, The Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada.
  • Fazli L; Department of Urologic Sciences, The Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada.
  • Haferkamp A; Department of Urology, University Medicine Johannes Gutenberg-University Mainz, Mainz, Germany.
  • Lejeune P; Bayer AG, Berlin, Germany.
  • Cherkasov A; Department of Urologic Sciences, The Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada.
  • Gleave ME; Department of Urologic Sciences, The Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada. Electronic address: m.gleave@ubc.ca.
Eur Urol ; 73(1): 4-8, 2018 01.
Article em En | MEDLINE | ID: mdl-28851578
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Feniltioidantoína / Neoplasias da Próstata / Pirazóis / Receptores Androgênicos / Resistencia a Medicamentos Antineoplásicos / Antagonistas de Receptores de Andrógenos Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: Eur Urol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Feniltioidantoína / Neoplasias da Próstata / Pirazóis / Receptores Androgênicos / Resistencia a Medicamentos Antineoplásicos / Antagonistas de Receptores de Andrógenos Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: Eur Urol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Alemanha